Xia Zhang1, Lizhi Lv2, Zhixian Wu1, Dongliang Li1, Kun Zhang3, Yonghai Peng4. 1. Department of Hepatobiliary Disease, The 900th Hospital of The People's Liberation Army Joint Service Support Force (Dongfang Hospital), Xiamen University Fuzhou 350025, Fujian Province, China. 2. Department of Hepatobiliary Surgery, The 900th Hospital of The People's Liberation Army Joint Service Support Force (Dongfang Hospital), Xiamen University Fuzhou 350025, Fujian Province, China. 3. Department of Hepatobiliary Surgery, Xiang'an Hospital of Xiamen University Xiamen 361101, Fujian Province, China. 4. Department of Oncology, The 900th Hospital of The People's Liberation Army Joint Service Support Force (Dongfang Hospital), Xiamen University Fuzhou 350025, Fujian Province, China.
Abstract
OBJECTIVE: To evaluate the impact of orthotopic liver transplantation (OLT) on postoperative quality of life (QoL), survival rate and recurrence rate of patients with liver cancer (LC). METHODS: One hundred and twenty-seven patients with LC treated in our hospital from December 2016 to January 2018 were divided into two groups according to different treatment schemes. Patients in the research group (n=67) were given OLT and those in the control group (n=60 cases) were given hepatectomy. The incidence of postoperative complications, hospitalization expenses, the time to liver function recovery, surgical wound healing, pain resolution and hospitalization were compared between the two groups. The overall survival rate (OSR), disease-free survival rate (DFSR), and average survival time of patients were recorded and compared. The Visual Analogue Scale (VAS) score one day and three days after surgery, alpha-fetoprotein (AFP) level, and adverse emotion before and after operation were compared. QoL scores at six months after surgery, one-year recurrence and metastasis rates, and treatment satisfaction one year after surgery were also compared. The expression of Ki-67 and Topo IIαin the tumor-bearing group (n=5) was detected. RESULTS: The research group presented markedly lower incidence of postoperative complications, and evidently shorter time to liver function recovery, surgical wound healing, pain resolution and hospitalization, while with noticeably higher hospitalization expenses. The one-year and five-year OSRs and DFSRs were noticeably higher, and the average survival time was remarkably longer in the research group as compared to the control group. Patients in the research group scored remarkably lower in VAS scores on the first and third day after surgery than patients in the control group. In comparison with the control group, the one-year recurrence and metastasis rates were evidently lower in the research group, and the scores of SF-36 were remarkably higher. The AFP level at one month after surgery was obviously lower in the research group, and the treatment satisfaction was greatly higher. Ki-67 in the tumor-bearing group was mainly located in the nucleus, and Topo IIα was mainly nucleus positive; the positive Ki-67 and Topo IIα expression rates in the tumor-bearing group was 66.7% and 69.8%, respectively. CONCLUSIONS: OLT can improve the postoperative QoL, survival rate and reduce the recurrence rate of LC patients. AJTR
OBJECTIVE: To evaluate the impact of orthotopic liver transplantation (OLT) on postoperative quality of life (QoL), survival rate and recurrence rate of patients with liver cancer (LC). METHODS: One hundred and twenty-seven patients with LC treated in our hospital from December 2016 to January 2018 were divided into two groups according to different treatment schemes. Patients in the research group (n=67) were given OLT and those in the control group (n=60 cases) were given hepatectomy. The incidence of postoperative complications, hospitalization expenses, the time to liver function recovery, surgical wound healing, pain resolution and hospitalization were compared between the two groups. The overall survival rate (OSR), disease-free survival rate (DFSR), and average survival time of patients were recorded and compared. The Visual Analogue Scale (VAS) score one day and three days after surgery, alpha-fetoprotein (AFP) level, and adverse emotion before and after operation were compared. QoL scores at six months after surgery, one-year recurrence and metastasis rates, and treatment satisfaction one year after surgery were also compared. The expression of Ki-67 and Topo IIαin the tumor-bearing group (n=5) was detected. RESULTS: The research group presented markedly lower incidence of postoperative complications, and evidently shorter time to liver function recovery, surgical wound healing, pain resolution and hospitalization, while with noticeably higher hospitalization expenses. The one-year and five-year OSRs and DFSRs were noticeably higher, and the average survival time was remarkably longer in the research group as compared to the control group. Patients in the research group scored remarkably lower in VAS scores on the first and third day after surgery than patients in the control group. In comparison with the control group, the one-year recurrence and metastasis rates were evidently lower in the research group, and the scores of SF-36 were remarkably higher. The AFP level at one month after surgery was obviously lower in the research group, and the treatment satisfaction was greatly higher. Ki-67 in the tumor-bearing group was mainly located in the nucleus, and Topo IIα was mainly nucleus positive; the positive Ki-67 and Topo IIα expression rates in the tumor-bearing group was 66.7% and 69.8%, respectively. CONCLUSIONS: OLT can improve the postoperative QoL, survival rate and reduce the recurrence rate of LC patients. AJTR
Authors: Marta Jover-Aguilar; Laura Martínez-Alarcón; Guillermo Ramis; José Antonio Pons; Antonio Ríos; Beatriz Febrero; Felipe Alconchel-Gago; César Carrillo; Alberto Inocencio Hiciano Guillermo; Pascual Parrilla; Pablo Ramírez Journal: Transplant Proc Date: 2020-04-08 Impact factor: 1.066
Authors: Marta Jover-Aguilar; Laura Martínez-Alarcón; Guillermo Ramis; Felipe Alconchel Gago; José Antonio Pons; Antonio Ríos; Beatriz Febrero; César Carrillo García; Alberto Inocencio Hiciano Guillermo; Pablo Ramírez Journal: Transplant Proc Date: 2020-02-10 Impact factor: 1.066
Authors: Jason B Liu; Talia B Baker; Nicholas R Suss; Mark S Talamonti; Kevin K Roggin; David J Winchester; Marshall S Baker Journal: Surgery Date: 2017-09-01 Impact factor: 3.982
Authors: Luciana Dos Santos Schraiber; Angelo Alves de Mattos; Maria Lucia Zanotelli; Guido Pio Cracco Cantisani; Ajácio Bandeira de Mello Brandão; Cludio Augusto Marroni; Guilhermo Kiss; Lucas Ernani; Patrícia Dos Santos Marcon Journal: Medicine (Baltimore) Date: 2016-01 Impact factor: 1.889